A case of atezolizumab-induced photodistributed bullous pemphigoid.


Journal

Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070

Informations de publication

Date de publication:
07 2019
Historique:
received: 03 04 2019
accepted: 05 04 2019
pubmed: 13 4 2019
medline: 25 2 2020
entrez: 13 4 2019
Statut: ppublish

Résumé

Immunotherapy has revolutionized cancer therapy in recent years but is associated with unique immunologically mediated adverse effects. Immunotherapy-induced bullous pemphigoid (BP) is an uncommon but established reaction that portends significant management implications as in most instances systemic treatment is required. We report a case of immunotherapy-associated BP in a marked photodistribution, highlighting the diverse clinical presentations of this eruption.

Identifiants

pubmed: 30977954
doi: 10.1111/dth.12924
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents 0
atezolizumab 52CMI0WC3Y

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12924

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Erica Leavitt (E)

Division of Dermatology, University of California, Los Angeles, California.

Vanessa Holland (V)

Division of Dermatology, University of California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH